Vecabrutinib (Synonyms: SNS-062)
目录号: PL01741 纯度: ≥99%
CAS No. :1510829-06-7
商品编号 规格 价格 会员价 是否有货 数量
PL01741-5mg 5mg ¥4945.45 请登录
PL01741-10mg 10mg ¥8036.36 请登录
PL01741-25mg 25mg ¥16690.91 请登录
PL01741-50mg 50mg ¥27200.00 请登录
PL01741-100mg 100mg ¥42036.36 请登录
PL01741-200mg 200mg 询价 询价
PL01741-500mg 500mg 询价 询价
PL01741-10mM*1mLinDMSO 10mM*1mLinDMSO ¥5761.45 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
Vecabrutinib
英文名称
Vecabrutinib
英文别名
Vecabrutinib;PQ7O0OB5GU;SNS062;FP0182;(3R,3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-[3-chloro-5-(trifluoromethyl)anilino]-2-oxo[1,3'-bipiperidine]-4'-carboxamide;Vecabrutinib [INN];Vecabrutinib [USAN];Vecabrutinib (USAN/INN);Vecabrutinib [USAN:INN];BIIB062;GTPL10231;(3R,4S)-1-(6-amino-5-fluoropyrimidin-4-yl)-3-[(3R)-3-[3-chloro-5-(trifluoromethyl)anilino]-2-oxopiperidin-1-yl]piperidine-4-carboxamide;BCP29646;SNS-062
Cas No.
1510829-06-7
分子式
C22H24ClF4N7O2
分子量
529.92
包装储存
Powder -20°C 3 years;4°C 2 years
产品详情
Vecabrutinib (SNS-062) 是一种有效的,非共价的 BTK 和 ITK 抑制剂,Kd 值分别为 0.3 nM 和 2.2 nM。Vecabrutinib 对 ITK 的 IC50 值为 24 nM。
生物活性
Vecabrutinib (SNS-062) is a potent, noncovalent BTK and ITK inhibitor, with K d values of 0.3 nM and 2.2 nM, respectively. Vecabrutinib shows an IC 50 of 24 nM for ITK.
性状
Solid
IC50 & Target[1][2]
IC50: 24 nM (ITK)
Kd: 0.3 nM (BTK), 2.2 nM (ITK)
体外研究(In Vitro)
Vecabrutinib inhibits pBTK in human whole blood with an average IC50 of 50 nM. Vecabrutinib inhibits WT and C481S BTK with similar IC50s (pBTK IC50s: WT BTK 2.9 nM, C481S BTK 4.4 nM). In a recombinant kinase assay, IC50s of Vecabrutinib against WT BTK and C481S BTK are 4.6 nM and 1.1 nM. Vecabrutinib retains activity against the mutated BTK variant. Vecabrutinib is six times more potent than PCI-32765 and greater than 640 times more potent than acalabrutinib against C481S BTK. Vecabrutinib demonstrates dose-dependent inhibition of BTK in primary patient CLL cells comparable to PCI-32765 via immunoblot for BTK phosphorylation. Vecabrutinib decreases viability of primary CLL cells in the presence of HS5 stromal protection by 5.5%. has not independently confirmed the accuracy of
体内研究(In Vivo)
Vecabrutinib has good oral bioavailability in rat and dog (%F ≥ 40%) and a terminal half-life of 5 to 6 hours. Vecabrutinib is well tolerated with continuous drug levels and at exposures much greater than those achieved for PCI-32765. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
ClinicalTrial
参考文献
[1]. Minke E. Binnerts, et al. Abstract C186: SNS-062 is a potent noncovalent BTK inhibitor with comparable activity against wild type BTK and BTK with an acquired resistance mutation. Molecular Cancer Therapeutics. December 2015 Volume 14, Issue 12 Supplement
[2]. Catherine A. Fabian, et al. Abstract 1207: SNS-062 demonstrates efficacy in chronic lymphocytic leukemia in vitro and inhibits C481S mutated Bruton tyrosine kinase. Cancer Research July 2017 Volume 77, Issue 13 Supplement
溶解度数据
In Vitro: DMSO : 125 mg/mL (235.88 mM; Need ultrasonic)配制储备液
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2